Sd-48 | 205048-68-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Sd-48
• 英文别名: 2-(3-Chlorophenyl)-4-phenyl-5,7-dihydropyrido[3,2-d][1]benzazepin-6-one
• CAS: 205048-68-6
• 化学式: C₂₅H₁₇ClN₂O
• 分子量: 396.876
• InChiKey: OUUZVUWPJALXST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Sd-48 在 diphosphorus pentasulfide 、 碳酸氢钠 作用下， 以 四氢呋喃 为溶剂， 以56%的产率得到2-(3-Chloro-phenyl)-4-phenyl-5,7-dihydro-1,7-diaza-dibenzo[a,c]cycloheptene-6-thione
  参考文献：
  名称：

  d-Fused [1]Benzazepines with Selective in Vitro Antitumor Activity:  Synthesis and Structure−Activity Relationships

  摘要：

  The synthesis of novel quinolino[3,2-d][1]benzazepines and pyrido[3,2-d][1]benzazepines is described. The in vitro antitumor activity of the compounds has been tested in the antitumor screening of the National Cancer Institute (NCI). Several 2,4-diarylpyrido[3,2-d][1]benzazepin-6-ones and -thiones turned out to exhibit considerable cytotoxicity for tumor cells. For studies of SAR within these series, substituents were introduced into the aromatic rings of the parent systems. Compounds from the thiolactam series tended to show higher potency than the corresponding lactams. Prominent compounds with noteworthy activity and remarkable selectivity for renal cancer cell lines are the lactams 10c, 10g, and 10h and the corresponding thiolactams 11c, 11g, and 11h. Methylation of the azepine nitrogen leads to complete loss of activity, whereas annelation of a triazolo ring at the lactam site or transformation of the thiolactam function to a thiolactim ether results in decreased antitumor activity and selectivity. Consequently, the secondary lactam or thiolactam structure of the seven-membered ring has to be regarded as essential for selective antitumor activity.

  DOI：

  10.1021/jm970675l
• 作为产物：
  描述：

  1H-[1]-苯并氮杂卓-2,5(3H,4H)-二酮 在 乙酸铵 、 氢氧化钾 、 ammonium ferric sulfate dodecahydrate 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 Sd-48
  参考文献：
  名称：

  d-Fused [1]Benzazepines with Selective in Vitro Antitumor Activity:  Synthesis and Structure−Activity Relationships

  摘要：

  The synthesis of novel quinolino[3,2-d][1]benzazepines and pyrido[3,2-d][1]benzazepines is described. The in vitro antitumor activity of the compounds has been tested in the antitumor screening of the National Cancer Institute (NCI). Several 2,4-diarylpyrido[3,2-d][1]benzazepin-6-ones and -thiones turned out to exhibit considerable cytotoxicity for tumor cells. For studies of SAR within these series, substituents were introduced into the aromatic rings of the parent systems. Compounds from the thiolactam series tended to show higher potency than the corresponding lactams. Prominent compounds with noteworthy activity and remarkable selectivity for renal cancer cell lines are the lactams 10c, 10g, and 10h and the corresponding thiolactams 11c, 11g, and 11h. Methylation of the azepine nitrogen leads to complete loss of activity, whereas annelation of a triazolo ring at the lactam site or transformation of the thiolactam function to a thiolactim ether results in decreased antitumor activity and selectivity. Consequently, the secondary lactam or thiolactam structure of the seven-membered ring has to be regarded as essential for selective antitumor activity.

  DOI：

  10.1021/jm970675l

文献信息

• CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Georgetown University

  公开号：EP2393787B1

  公开（公告）日：2018-01-24
• Cadherin-11 Inhibitors and Methods of Use Thereof
  申请人：Georgetown University

  公开号：US20150064168A1

  公开（公告）日：2015-03-05

  Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis.
• USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：US20170360934A1

  公开（公告）日：2017-12-21

  Provided herein are methods and pharmaceutical compositions for the treatment of obesity-associated conditions using cadherin-11 antagonists.
• US8802687B2
  申请人：——

  公开号：US8802687B2

  公开（公告）日：2014-08-12
• US9284368B2
  申请人：——

  公开号：US9284368B2

  公开（公告）日：2016-03-15